CTMX: Cash Cushion and Near-Term Investor Events Make a Tactical Long Worth Considering
CytomX has materially strengthened its balance sheet via a $250M equity offering and is approaching two high-profile healthcare conferences in early June where management will present program updates. The stock is still cheap on an enterprise-value-to-revenue basis only because revenues are very small; the trade is a tactical long that leans on cas…